vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and LINDSAY CORP (LNN). Click either name above to swap in a different company.
LINDSAY CORP is the larger business by last-quarter revenue ($150.7M vs $86.8M, roughly 1.7× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -6.1%). LINDSAY CORP produced more free cash flow last quarter ($-15.1M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 1.3%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Lindsay Corporation, formerly known as Lindsay Manufacturing Co., is a manufacturer of Zimmatic brand center pivot irrigation systems, based in Omaha, Nebraska, United States. It also manufactures farm and construction machinery, as well as road and railroad infrastructure equipment. At August 31, 2008, the company had 1,239 employees.
IOVA vs LNN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $150.7M |
| Net Profit | — | $16.5M |
| Gross Margin | 67.4% | 33.3% |
| Operating Margin | -84.7% | 13.0% |
| Net Margin | — | 11.0% |
| Revenue YoY | 17.7% | -6.1% |
| Net Profit YoY | — | -3.7% |
| EPS (diluted) | — | $1.54 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $150.7M | ||
| Q3 25 | $67.5M | $149.0M | ||
| Q2 25 | $60.0M | $165.7M | ||
| Q1 25 | $49.3M | $183.8M | ||
| Q4 24 | $73.7M | $160.5M | ||
| Q3 24 | $58.6M | $149.4M | ||
| Q2 24 | $31.1M | $133.7M | ||
| Q1 24 | $715.0K | $146.8M |
| Q4 25 | — | $16.5M | ||
| Q3 25 | $-91.3M | $10.8M | ||
| Q2 25 | $-111.7M | $19.5M | ||
| Q1 25 | $-116.2M | $26.6M | ||
| Q4 24 | — | $17.2M | ||
| Q3 24 | $-83.5M | $12.7M | ||
| Q2 24 | $-97.1M | $20.4M | ||
| Q1 24 | $-113.0M | $18.1M |
| Q4 25 | 67.4% | 33.3% | ||
| Q3 25 | 43.0% | 30.0% | ||
| Q2 25 | 5.5% | 32.4% | ||
| Q1 25 | -0.8% | 34.0% | ||
| Q4 24 | 68.7% | 31.1% | ||
| Q3 24 | 46.2% | 30.6% | ||
| Q2 24 | -0.8% | 34.8% | ||
| Q1 24 | — | 33.3% |
| Q4 25 | -84.7% | 13.0% | ||
| Q3 25 | -140.7% | 7.6% | ||
| Q2 25 | -189.8% | 14.4% | ||
| Q1 25 | -245.8% | 17.5% | ||
| Q4 24 | -117.5% | 13.0% | ||
| Q3 24 | -152.1% | 9.0% | ||
| Q2 24 | -327.6% | 14.9% | ||
| Q1 24 | -16464.6% | 15.1% |
| Q4 25 | — | 11.0% | ||
| Q3 25 | -135.3% | 7.3% | ||
| Q2 25 | -186.2% | 11.8% | ||
| Q1 25 | -235.5% | 14.5% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | -142.7% | 8.5% | ||
| Q2 24 | -312.2% | 15.2% | ||
| Q1 24 | -15800.8% | 12.3% |
| Q4 25 | — | $1.54 | ||
| Q3 25 | — | $0.99 | ||
| Q2 25 | $-0.33 | $1.78 | ||
| Q1 25 | $-0.36 | $2.44 | ||
| Q4 24 | $-0.24 | $1.57 | ||
| Q3 24 | $-0.28 | $1.16 | ||
| Q2 24 | $-0.34 | $1.85 | ||
| Q1 24 | $-0.42 | $1.64 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $199.6M |
| Total DebtLower is stronger | — | $115.2M |
| Stockholders' EquityBook value | $698.6M | $518.2M |
| Total Assets | $913.2M | $828.4M |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $199.6M | ||
| Q3 25 | $300.8M | $250.6M | ||
| Q2 25 | $301.2M | $210.8M | ||
| Q1 25 | $359.7M | $186.7M | ||
| Q4 24 | $323.8M | $194.1M | ||
| Q3 24 | $397.5M | $190.9M | ||
| Q2 24 | $412.5M | $152.7M | ||
| Q1 24 | $356.2M | $150.6M |
| Q4 25 | — | $115.2M | ||
| Q3 25 | — | $115.3M | ||
| Q2 25 | — | $115.3M | ||
| Q1 25 | — | $115.4M | ||
| Q4 24 | — | $115.4M | ||
| Q3 24 | — | $115.5M | ||
| Q2 24 | — | $115.5M | ||
| Q1 24 | — | $115.6M |
| Q4 25 | $698.6M | $518.2M | ||
| Q3 25 | $702.3M | $532.9M | ||
| Q2 25 | $698.5M | $528.8M | ||
| Q1 25 | $767.9M | $516.4M | ||
| Q4 24 | $710.4M | $488.5M | ||
| Q3 24 | $773.5M | $480.9M | ||
| Q2 24 | $768.5M | $480.0M | ||
| Q1 24 | $680.0M | $483.0M |
| Q4 25 | $913.2M | $828.4M | ||
| Q3 25 | $904.9M | $840.8M | ||
| Q2 25 | $907.4M | $840.9M | ||
| Q1 25 | $966.7M | $814.2M | ||
| Q4 24 | $910.4M | $771.0M | ||
| Q3 24 | $991.1M | $760.2M | ||
| Q2 24 | $964.3M | $758.1M | ||
| Q1 24 | $869.8M | $765.3M |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.22× | ||
| Q1 25 | — | 0.22× | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | — | 0.24× | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | — | 0.24× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $-597.0K |
| Free Cash FlowOCF − Capex | $-61.9M | $-15.1M |
| FCF MarginFCF / Revenue | -71.3% | -10.0% |
| Capex IntensityCapex / Revenue | 10.7% | 9.6% |
| Cash ConversionOCF / Net Profit | — | -0.04× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $62.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $-597.0K | ||
| Q3 25 | $-78.7M | $64.0M | ||
| Q2 25 | $-67.4M | $35.0M | ||
| Q1 25 | $-103.7M | $12.3M | ||
| Q4 24 | $-73.3M | $21.6M | ||
| Q3 24 | $-59.0M | $53.1M | ||
| Q2 24 | $-98.4M | $30.5M | ||
| Q1 24 | $-122.3M | $-9.7M |
| Q4 25 | $-61.9M | $-15.1M | ||
| Q3 25 | $-89.5M | $49.8M | ||
| Q2 25 | $-74.9M | $25.7M | ||
| Q1 25 | $-109.9M | $2.5M | ||
| Q4 24 | $-77.5M | $12.5M | ||
| Q3 24 | $-61.3M | $47.7M | ||
| Q2 24 | $-98.9M | $25.8M | ||
| Q1 24 | $-126.5M | $-21.6M |
| Q4 25 | -71.3% | -10.0% | ||
| Q3 25 | -132.7% | 33.4% | ||
| Q2 25 | -124.9% | 15.5% | ||
| Q1 25 | -222.8% | 1.4% | ||
| Q4 24 | -105.1% | 7.8% | ||
| Q3 24 | -104.6% | 31.9% | ||
| Q2 24 | -317.9% | 19.3% | ||
| Q1 24 | -17685.3% | -14.7% |
| Q4 25 | 10.7% | 9.6% | ||
| Q3 25 | 16.1% | 9.6% | ||
| Q2 25 | 12.4% | 5.6% | ||
| Q1 25 | 12.6% | 5.3% | ||
| Q4 24 | 5.7% | 5.7% | ||
| Q3 24 | 3.9% | 3.6% | ||
| Q2 24 | 1.4% | 3.6% | ||
| Q1 24 | 583.4% | 8.1% |
| Q4 25 | — | -0.04× | ||
| Q3 25 | — | 5.92× | ||
| Q2 25 | — | 1.79× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 1.26× | ||
| Q3 24 | — | 4.17× | ||
| Q2 24 | — | 1.50× | ||
| Q1 24 | — | -0.54× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
LNN
| Transferred At Point In Time | $133.2M | 88% |
| Infrastructure | $13.4M | 9% |
| Transferred Over Time | $8.0M | 5% |
